DCRI’s CEC Group Contributes to AHA Late-Breakers
AHA 2020: RIVER Shows Rivaroxaban Safe for Patients with Bioprosthetic Valves
AHA 2020: GALACTIC-HF Finds Investigational Therapy to be Effective
PROVIDE-HF Finds Early Improvements in Quality of Life in Patients with Heart Failure Treated with Sacubitril/Valsartan
By evaluating patient-reported and electronic health record data, the pragmatic clinical study adds important real-world evidence to inform clinical practice.
DCRI Selected as U.S. Coordinating Center for NIH ACTIV-1 Trial
The DCRI has received $44 million in funding to examine whether three immune modulators help prevent overactive immune response in moderate or severe cases of COVID-19.
TCT 2020: New One-year Follow Up Results Shed Light on Optimal Care After PCI
Clinical Trials ‘System is Working,’ Hernandez Says
DCRI Launches First Direct-to-Family Study to Improve Medication Dosing and Adherence in Children and Teens with Lupus
The clinical study's home-based design combines on-site nursing visits and mobile technology to embed research into patients' lives.
At DCRI, Collaborations Lead to Better Evidence
Building on DCRI’s strong history in building cardiovascular evidence, researchers at the Institute with a wide range of expertise are also considering how cardiovascular disease factors into other
ESC 2020: Randomized Trial Confirms ACEI/ARB Safety for Patients with COVID-19
EDITORS' NOTE: This story was updated January 19, 2021 when the study was published in Journal of the American Medical Association.